Sri Rama Krishna Paruchuri, MD
Pulmonary Disease · Rio Rancho, NMNPI 1104057389
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 166 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 23.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,879 and has fallen 67.9% since, to $604 in 2025.
Across 166 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$941
- GSK$581
- Boehringer Ingelheim$438
- Grifols USA, LLC$415
- Intuitive Surgical$340
- Regeneron Healthcare Solutions, Inc.$244
- plus $1K from 22 others
What the payments were for
- Food & beverage$4,029100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 42 | $941 |
| GSK | 34 | $581 |
| Boehringer Ingelheim | 15 | $438 |
| Grifols USA, LLC | 19 | $415 |
| Intuitive Surgical | 3 | $340 |
| Regeneron Healthcare Solutions, Inc. | 11 | $244 |
| Haemonetics Corporation | 2 | $132 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $129 |
| Jazz Pharmaceuticals Inc. | 3 | $84 |
| Sanofi | 3 | $71 |
| AbbVie | 3 | $68 |
| Bayer | 1 | $68 |
| Mylan Specialty L.p. | 3 | $68 |
| Actelion Pharmaceuticals US, Inc. | 2 | $50 |
| Abiomed | 1 | $49 |
| Pfizer | 3 | $47 |
| Vifor Pharma, Inc. | 2 | $45 |
| Novartis | 2 | $41 |
| Amgen | 2 | $37 |
| Coaptech, Inc. | 1 | $34 |
| Lilly USA, LLC | 2 | $28 |
| Insmed, Inc. | 1 | $25 |
| Tactile Systems Technology Inc | 1 | $19 |
| Philips North America LLC | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Viatris Specialty LLC | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $15 |
| United Therapeutics Corporation | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$240
- Prolastin-C Liquid$120
- OFEV$104
How this compares
$4,029 in reported general payments places this provider in the 80th percentile of 56 pulmonary disease providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 37 | $465,093 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 108 | $101,382 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 106 | $90,806 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 103 | $62,290 |
| Dupixent PenDupilumab | 14 | $51,434 |
| Spiriva RespimatTiotropium Bromide | 79 | $49,907 |
| Breo ElliptaFluticasone/Vilanterol | 50 | $21,641 |
| Advair HfaFluticasone Propion/Salmeterol | 48 | $16,885 |
| Incruse ElliptaUmeclidinium Bromide | 41 | $15,232 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 19 | $13,416 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 31 | $12,376 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 61 | $11,805 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $8,552 |
| Arnuity ElliptaFluticasone Furoate | 26 | $7,796 |
| DuleraMometasone/Formoterol | 18 | $7,627 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $438 | $577,290219 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta, Arnuity Ellipta | $581 | $158,428256 claims |
| AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort | $941 | $112,775152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 56 pulmonary disease providers in New Mexico.
Other pulmonary disease in Rio Rancho
- Lana Melendres GrovesAlbuquerque$1.1M
- Luke GabeSanta Fe$47K
- Michelle HarkinsAlbuquerque$24K
- Viral GandhiAlbuquerque$14K
- Gonzalo DiazAlamogordo$14K
- Arjan FloraAlbuquerque$10K
- Akshay SoodAlbuquerque$9K
- Alan OrellanaLas Cruces$5K
- Sivakumar NagarajuAlbuquerque$5K
- Alejandro ArzabalaLas Cruces$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.